Suredip Concentrate

Main information

  • Trade name:
  • Suredip Concentrate
  • Pharmaceutical form:
  • Teat dip concentrate
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Suredip Concentrate
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Cattle Lactating, Goats Lactating, Sheep Lactating

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0161/001
  • Authorization date:
  • 15-12-2011
  • EU code:
  • UK/V/0161/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:December2011

AN:01307/2011

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

UK:SUREDIP3.7%CONCENTRATEforTeatDiporTeatSpray

Eire:HEXAGUARD3.7%CONCENTRATEforTeatDiporTeatSpray

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

ActiveIngredient:

Chlorhexidinegluconatesolution(20%Ph.Eur)toprovideconcentrationof

Chlorhexidinegluconate3.70%w/v.

Otherconstituents:Fulllistofexcipientsisgivenin6.1

1.LanolinCompound

2.Glycerol

3.Alcohol6molethoxylate:3molepropoxylate

4.Ethyleneoxide/propyleneoxideblockco-polymer

5.PatentblueV(dye –E131)

6.Waterdeionised

3. PHARMACEUTICALFORM

ConcentrateforTeatDiporTeatSpraysolution

Requiresdilutionbeforeuse

4. CLINICALPARTICULARS

Thisproductcontainschlorhexidinegluconateasabiocide.Theagentisa

bactericidaldisinfectantwhichbelongstothebiquanidinegroupof

cationicsurfactantsthatactbydisruptingcellularmatter.

Theemollientsaidinteatcareandhealth.

4.1 Targetspecies

Pregnantandlactatingdairycows,sheepandgoats

4.2 Indicationsforuse,specifyingthetargetspecies

Whenusedasateatdip/teatsprayisanaidinthepreventionofthe

spreadofmastitisinlactatingdairycattle,sheepandgoats.

Revised:December2011

AN:01307/2011

Page2of5

4.3 Contraindications

None

4.4 Specialwarningsforeachtargetspecies

Forexternaluseonly.

4.5 Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

Washanddryuddersandteatsbeforenextmilking.Emptyteatdipping

beakersaftereachmilkingandwashbeforereuse.

Ifsignsofdiseasepersistorappearconsultyourveterinarysurgeon.

ii. Specialprecautionsforthepersonadministeringtheveterinarymedicinal

producttoanimals

Avoidcontactwitheyes.Ifsplashedintheeye,rinsewithcleanrunning

waterandseekmedicaladvice.

Incaseofingestionseekmedicaladviceimmediately.

Whenusedasaspray,avoidworkinginaspraymist.

Keepawayfromanimalfeed.

Washhandsafteruse.

iii.

Otherprecautions

None.

4.6 Adversereactions(frequencyandseriousness)

SkinsensitivitytoChlorhexidineisrareandnosuspectedadverse

reactionshavebeenreportedsofar.

4.7 Useduringpregnancy,lactationorlay

Foruseinpregnantandlactatingcows,sheepandgoats.Theproductis

amedicinaldisinfectantforexternalapplicationasanaidagainstmastitis.

4.8 Interactionwithothermedicinalproductsandotherformsof

interaction

Donotuseinconjunctionwithanyothertreatmentfordisinfectionof

teats/udders –notcompatiblewithiodinebasedteatdips.

Revised:December2011

AN:01307/2011

Page3of5

4.9

Amount(s)tobeadministeredandadministrationroute

SuredipConcentrateisapreparationthatshouldbedilutedpriorto

use.

TeatDipping

Makeupastocksolutiondailybydiluting1partofSuredip(Hexaguard)

Concentratewith4partsofwater.Thestocksolutionwillcontain7400

ppmchlorhexidinegluconate.

Fillthedippingbeakerstwothirds(2/3)fullandapplytotheteatsofthe

lactatingcows,sheeporgoatsimmediatelyaftermilking.Thedipping

beakersshouldbeemptiedaftereachmilkingandwashedbeforereuse.

Replenishdippingbeakersaftereachmilking.

TeatSpraying

Makeastocksolutiondailybydiluting1partofSuredip(Hexaguard)

Concentrateto4partsofwater.Immediatelyafterthemilkingofcows,

sheepandgoatsspraytheentiresurfaceofeachteat.Thestocksolution

willcontain7400ppmchlorhexidinegluconate.

4.10 Overdose(symptoms,emergencyprocedures,antidotes),if

necessary

Notapplicable –externalteatsurfacetreatmentonly.

4.11 Withdrawalperiod(s)

MeatandMilk:Zerodays

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:

VeterinaryDisinfectant:Dermatologicals:

Antisepticsanddisinfectants:Chlorhexidine

ATCVetCode:QD08AC02

5.1 Pharmacodynamicproperties

Theactiveingredientisadisinfectantwithbactericidalactivityagainst

mostbacteria.Thepostmilkingtopicalapplicationofthe(diluted)product

totheteatsoflactatingcows,sheepandgoatspreventstheingressof

pathogenicorganismsintothestreakcanaloftheteatandtherebyaidsin

thepreventionofthespreadofmastitisfrominfectedquarterstonon-

infectedquarters.

5.2 Pharmacokineticproperties

Revised:December2011

AN:01307/2011

Page4of5

WorkdonebytheInstituteforAnimalHealth,Compton,Newbury,UKin

1991demonstratesthatpostmilkingtopicalapplicationoftheproductto

theteatsoflactatingcows,resultedintheabsorptionintomilkofalevelof

theactiveingredientnotexceeding10ppb.

6.

PHARMACEUTICALPARTICULARS

Suredip(Hexaguard)Concentrateisapreparationthatshouldbediluted

priortousewhichcontainschlorhexidinegluconateandemollientsasan

aidinthepreventionofthespreadofmastitisinlactatingdairycattle,

sheepandgoats.

6.1 Listofexcipients

Glycerol(CASNo.56-81-5),

WatersolubleLanolincompound(CASNo.61790-81-6),

PatentblueV(dye –E131),

polymericnon-ionicsurfactants:Alcohol6moleethoxylate:3mole

propoxylate(CASNo.68154-97-2)andEthyleneoxide/propyleneoxide

blockcopolymer(CASNo.90003-11-6)

6.2 Incompatibilities

Chlorhexidinegluconateisincompatiblewithsoapsorwashingupliquids

oranionicsurfactants.Donotmixwithsodiumhypochloritesolutionsor

alkalinemixtures.

Donotmixwithiodinebasedteatdips.

6.3 Shelflife

Twoyears

6.4 Specialprecautionsforstorage

Storeoutofthereachandsightofchildren.

Donotstoreabove25°C.

Protectfromfrost.

Protectfromdirectsunlight.

6.5 Natureandcompositionofimmediatepackaging

SuredipConcentrateispackedin:

1.5litreliquidteatdipinblowmouldedhighdensitypolyethylene

jerricanstylecontainerscompletewithtamperevidentscrewcap

2.20,25and45Lliquidteatdipinanaturalsquare/roundhigh

Revised:December2011

AN:01307/2011

Page5of5

densitypolythenecontainerwithscrewcap(tamperevident)

closure.

3.200Lliquidteatdipinacylindricalpolyethylenecontainerwith

combinationbung.

6.6 Specialprecautionsforthedisposalofunusedveterinary

medicinalproductorwastematerialsderivedfromtheuseofsuch

products,ifappropriate

Anyunusedveterinarymedicinalproductorwastematerialsderivedfrom

suchveterinarymedicinalproductsshouldbedisposedofinaccordance

withlocalrequirements.

Harmfultofish.Donotcontaminatepondsorditcheswiththisproductor

usedcontainer.

7. MARKETINGAUTHORISATIONHOLDER

GEAFarmTechnologies(UK)Ltd

WylyeWorks

WateryLane

Bishopstrow

Warminster

Wiltshire

BA129HT

8. MARKETINGAUTHORISATIONNUMBER(S)

UK: Vm 01808/4013Eire:VPA10844/4/1

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHE

AUTHORISATION

Date:1 st

August2002

10. DATEOFREVISIONOFTHETEXT

Date:December2011

Conditionsofsale,supplyand/oruse:

Inaccordancewithnationalrequirements.

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

5-6-2018

FDA warns companies to stop selling dangerous and illegal pure and highly concentrated caffeine products

FDA warns companies to stop selling dangerous and illegal pure and highly concentrated caffeine products

FDA issued warning letters to the parties responsible for liquidcaffeine.com and Dual Health Body and Mind for illegally selling certain highly concentrated caffeine products.

FDA - U.S. Food and Drug Administration

2-10-2018

NexoBrid (MediWound Germany GmbH)

NexoBrid (MediWound Germany GmbH)

NexoBrid (Active substance: Concentrate of proteolytic enzymes enriched in bromelain) - PSUSA - Modification - Commission Decision (2018)6460 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10028/201712

Europe -DG Health and Food Safety

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency